Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

519.40INR
3 Aug 2020
Change (% chg)

-- (--)
Prev Close
Rs519.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,009,967
52-wk High
Rs541.00
52-wk Low
Rs312.00

Select another date:

Mon, Jun 29 2020

BRIEF-Sun Pharma Unit Gets Japan's Nod For ILUMYA To Treat Plaque Psoriasis

* UNIT GETS JAPAN MHLW APPROVAL OF ILUMYA FOR TREATMENT OF PLAQUE PSORIASIS Source text for Eikon: Further company coverage:

BRIEF-Sun Pharma, Hikma Sign Exclusive Licensing Deal For Ilumya For MENA Region

* SUN PHARMA AND HIKMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR ILUMYA FOR MIDDLE EAST & NORTH AFRICA REGIONS

Sun Pharma testing plant-based drug as potential COVID-19 treatment

BENGALURU Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October.

Sun Pharma testing plant-based drug as potential COVID-19 treatment

BENGALURU, June 5 Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October.

Sun Pharma to test pancreatitis drug in COVID-19 patients in India

BENGALURU Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.

BRIEF-Sun Pharma Gets Indian Regulatory Nod For Nafamostat Study In COVID-19 Patients

* RECEIVES APPROVAL FROM DCGI TO INITIATE CLINICAL TRIAL WITH NAFAMOSTAT IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:

Sun Pharma to test pancreatitis drug in COVID-19 patients in India

BENGALURU Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.

UPDATE 1-Sun Pharma to test pancreatitis drug in COVID-19 patients in India

BENGALURU, May 29 Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.

India's Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

BENGALURU, May 29 Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

BRIEF-Sun Pharmaceutical Industries Says Co, SPARC Enter Worldwide License Agreement For SCD-044

* SUN PHARMACEUTICAL INDUSTRIES LTD - SPARC AND SUN PHARMA ENTER INTO A WORLDWIDE LICENSE AGREEMENT FOR SCD-044

Select another date: